

A clinical briefing on Aller-Cort (Triamcinolone nasal spray) availability in 2026. What providers need to know about supply, alternatives, and patient guidance.
Your patients are asking about Aller-Cort. Many are reporting difficulty finding this popular Costco Kirkland Signature brand of Triamcinolone Acetonide nasal spray, particularly during peak allergy season. As a prescriber, understanding the current supply landscape helps you guide patients effectively and ensure continuity of care.
This briefing covers the current status of Aller-Cort and Triamcinolone nasal spray availability, clinical implications, cost considerations, and practical recommendations for your practice.
As of March 2026, Triamcinolone Acetonide nasal spray is not listed as being in shortage by the FDA Drug Shortage Database or the ASHP Drug Shortage Resource Center. Manufacturing and distribution of the active pharmaceutical ingredient remain uninterrupted.
What patients are experiencing with Aller-Cort specifically are localized, demand-driven stock-outs at Costco warehouse locations. This pattern is consistent with seasonal demand surges for OTC allergy medications and is amplified by Aller-Cort's limited distribution footprint (Costco-exclusive product).
Because Aller-Cort and its equivalents (Nasacort, generic Triamcinolone nasal spray) are available over the counter, most patients self-manage their allergic rhinitis without a prescription. However, patient inquiries about availability may present opportunities to:
All OTC intranasal corticosteroids have demonstrated similar efficacy in clinical trials for allergic rhinitis. The available options include:
For patients with moderate-to-severe allergic rhinitis not adequately controlled by monotherapy, Azelastine/Fluticasone (Dymista) — a prescription combination of an intranasal antihistamine and corticosteroid — may offer superior symptom control.
Patients presenting with difficulty finding their OTC nasal spray may benefit from a clinical conversation about whether their current treatment is adequate. Consider escalation to:
The broader availability of Triamcinolone nasal spray and equivalent intranasal corticosteroids remains strong:
Patients who specifically want the Aller-Cort brand for its lower price point ($12–$18 per bottle) should be counseled that generic Triamcinolone from other retailers typically costs $20–$22 with a discount card, and store-brand generics of other nasal steroids may be comparably priced.
As OTC medications, intranasal corticosteroids are not subject to insurance formulary restrictions or prior authorization requirements. However, cost remains a factor for patients:
For detailed cost information, see our guide on how to help patients save money on Aller-Cort.
Medfinder for Providers offers tools to help clinical teams check medication availability and guide patients to pharmacies with stock. Key features include:
You can also direct patients to the following educational resources:
The intranasal corticosteroid market is stable and competitive, with no anticipated supply disruptions. Key trends to watch in 2026 and beyond include:
While Aller-Cort specifically may be intermittently difficult to find due to its Costco-exclusive distribution, the underlying medication — Triamcinolone Acetonide nasal spray — and its therapeutic equivalents remain widely available and affordable. Providers can reassure patients, counsel on equivalent alternatives, and use this as an opportunity to review allergy treatment plans.
For practice tools and patient resources, visit Medfinder for Providers.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.